Octimibate is a non-prostanoid inhibitor of platelet aggregation that acts via the prostacyclin receptor.

Gliamilide is a high-potency sulfamylurea hypoglycemic agent. It has been found to be well tolerated in humans and displays a very short plasma half-life. Like sulfonylureas, gliamilide can lower blood glucose levels by increasing the insulin release from pancreatic beta cells.

Spiclamine (Epsilamine) is a hemostatic agent. It was administered to a total of 23 patients with urological diseases, including 8 postoperative cases. Marked effective, effective and ineffecgive responses were observed in 8, 10 and 5 cases respectively, making 78.3 % of effectiveness. In cases of so-called essential renal bleeding and prostatic disease, a particularly beneticial result was obtained making 93.3 % of marked effectiveness. No serious side effects was seen in all cases treated.

Glyprothiazol (VK 57 or RP 2254) is a sulfonamide derivative. This compound lowers blood glucose levels by increasing the release of insulin from the pancreas. It stimulates insulin secretion through a direct action on pancreatic islets. Glyprothiazol was the first of oral hypoglycemic sulfonamides used in the treatment of type 2 diabetes mellitus.

Halocortolone, a synthetic glucocorticoid that was used as a vasoconstrictor, but was never marketed

Azepexole (or previously known as B-HT 933), a selective alpha 2-adrenoceptor agonist that was studied for the man with physiological tremor. It was shown that the drug produced sedation compared to placebo but not when compared to pre-treatment values. Some studies also have revealed the anti-tussive and antihypertensive properties of azepexole.

Pimetremide is a spasmolytic agent.

Atiratecan (previously known as CH4556300 or TP300), the prodrug of a topoisomerase 1 inhibitor, CH0793076. Atiratecan has been studied in phase II clinical trials to treat cancers (e.g., colorectal cancer; gastric cancer; esophageal cancer), but these studies were suspended.

Sulicrinat (also known as HOE 428) is a sulfamoylbenzophenone derivative patented by Hoechst A.-G. as a loop diuretic.

Tiomolibdic acid salt, Bis-choline tetrathiomolybdate (ATN-224, WTX-101), is under investigation as a therapy against different cancers and Wilson’s disease (WD). ATN-224 is a second-generation analog of ammonium tetrathiomolybdate. ATN-224 is a novel copper chelator. ATN-224 inhibits CuZn superoxide dismutase 1 (SOD1) leading to antiangiogenic and antitumor effects. Strategically tailoring combination regimens that include ATN-224 and target ROS may be a viable approach to advance the treatment of melanoma. ATN-224 is in phase III clinical trial for the treatment of Hepatolenticular degeneration. WTX-101 is in phase II clinical trials for the treatment of Wilson's disease. Once daily WTX-101 treatment over 24 weeks improved neurologic disease, hepatic status and copper control in newly diagnosed WD patients. WTX-101 appears well tolerated. Drug-induced, paradoxical, neurological deterioration was not observed. This compound has received orphan drug designation in both the United States and the European Union. WTX-101 was originally discovered by University of Michigan and now is being developed by Wilson Therapeutics by acquisition.